BUZZ-泰拉生物科学股价暴跌,因其抗癌药物未达华尔街预期9月9日 - ** 泰拉生物科学公司(TYRA.O)股价在盘前交易中下跌24.8%,至20.10美元
** Tyra表示,其实验性膀胱癌药物达博格拉替尼(dabogratinib)在60毫克剂量下,3个月 (link) 完全缓解率达57%
** 在数据公布前,Piper Sandler的分析师曾将“70%的3个月完全缓解率”设定为首要的“成功门槛”
** 杰富瑞(Jefferies)曾预测股价反应范围为:“若完全缓解率落在70%至79%区间,股价将上涨20%-30%”;“若3个月完全缓解率低于70%,股价将下跌30%”
** 该口服药物旨在靶向并阻断FGFR3基因突变,该突变会促进某类低级别膀胱癌患者的肿瘤生长
** Tyra 还计划就晚期临床试验的设计和剂量选择与卫生监管机构进行沟通
** 截至上一交易日收盘,该股年初至今累计上涨1.7%
At the request of the copyright holder, you need to log in to view this content
LOGIN / SIGN UPDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.